Trans-Atlantic inter-society consensus document II on peripheral arterial qisapse - TASC II

Acta Chirurgica Belgica

Volumn 107, Issue 3 SUPPL., 2007, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547354361     PISSN: 00015458     EISSN: 25770160     Source Type: Journal    
DOI: None     Document Type: Review

References (227)

1. TASC. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vase Endovasc Surg, 2000, 19 Suppl A : Sixxviii, S1-S250.
2. TASC. Management of Peripheral Arterial Disease (PAD) TransAtlantic Intersociety Consensus (TASC). J Vase Sura2000, 31 (1 part 2): S1-S287.
3. TASC. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Int Angiol, 2000, 19 (1 Suppl 1) : I-XXIV, 1-304.
4. CLEMENT D. L., BOCCALON H., DORMANCY J., DURAND ZALESKI I., FOWKES G., BROWN T. A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis). Int Angiol, 2000. 19 (2) : 97-125.
5. HIRSCH A. T., HASKAL Z. J., HERTZER N. R., BAKAL C. W., CREAGER M. A., HALPERIN J. L. et al. ACC/AHA, 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic) : executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery. Society for Cardiovascular Angiography and Interventions. Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) dorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, National Heart. Lung, and Blood Institute, Society for Vascular Nursing. TransAtlantic Inter-Society Consensus, and Vascular Disease Foundation. J Am Coll Cordial, 2006, 47 (6) : 1239-312.
6. AHCPR. United States Department of Health and Human Services. Agency for Health Care Policy and Research. Acute pain management : operative on medical procedures and trauma. [107]. Rockville MD : AHCPR, 1993.
7. CRIQUI M. H., FRONEK A., BARRETT-C ONNOR E., KLAUBER M. R., GABRIEL S., GOODMAN D. The prevalence of peripheral arterial disease in a defined population. Circulation, 1985. 71 (3) : 510-551.
8. HIATT W. R., HOAG S., HAMMAN R. F. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation, 1995, 91 (5) : 1472-1479.
9. SELVIN E., ERLINOER T. P. Prevalence of and risk factors for peripheral arterial disease in the United States : results from the National Health and Nutrition Examination Survey. 1999-2000. Circulation, 2004, 110 (6) : 738-743.
10. FOWKES F. G., HOUSLEY E., CAWOOD E.H., MACINTYRE C. C., RUCKLEY C. V., PRESCOTT R. J. Edinburgh Artery Study : prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991. 20 (2) : 384-392.
11. HIRSCH A., CRIQUI M., TREAT-JACOBSON D., REGENSTEINER J., CREAGER M., OLIN J. et al. Peripheral arterial disease detection. awareness, and treatment in primary care. JAMA, 2001. 286 (11) : 1317-1324.
12. CRIQUI M. H., VARGAS V, DENENBERG J. O., HO E., ALLISON M., LANGER R. D. et al. Ethnicity and peripheral arterial disease : the San Diego Population Study. Circulation, 2005. 112 (17): 2703-2707.
13. KULLO I. J,, BAILEY K. R., KARDIA S. L., MOSLF.Y T. H., Jr., BOERWINKLE E., TURNER S. T. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vase Med, 2003, 8 (4) : 237-242.
14. SELVIN E., MARINOPOULOS S., BERKENBLIT G., RAMI T., BRANCATI F. L., POWE N. R. et al. Meta-analysis : glycosylatcd hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med, 2004, 141 (6) : 421-431.
15. MUNTNER P., WILDMAN R. P., REYNOLDS K., DESALVO K. B., CHEN J., FONSECA V. Relationship between HbAlc level and peripheral arterial disease. Diabetes Care, 2005, 28 (8) : 1981-1987.
16. ADA. Peripheral arterial disease in people with diabetes. Diabetes Care, 2003, 26 (12) : 3333-3341.
17. SENTI M., NOGUES X., PEDRO-BOTET J., RUBIES-PRAT J., VIDAI.-BARRAQUER F. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation, 1992, 85 (1) : 30-36.
18. RIDKER P.M., STAMPFER M.J., RIFAI N. Novel risk factors for systemic atherosclerosis : a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA, 2001, 285 (19): 2481-2485.
19. O'HARE A.M., VITTINGHOFF E., HSIA J., SHLIPAK M. G. Renal insufficiency and the risk of lower extremity peripheral arterial disease : results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol, 2004, IS (4) : 1046-1051.
20. MCDERMOTT M. M., CRIQUI M. H., GREENLAND P., GURALNIK J. M., LIU K., PEARCE WH. et al. Leg strength in peripheral arterial disease : associations with disease severity and lower-extremity performance. J Vase Surg, 2004, 39 (3) : 523-530.
21. WIDMER L., BILAND L. Risk profile and occlusive peripheral arterial disease. Proceedings of 13th International Congress of Angiology, 1985 : 28.
22. KANNEL W. B., SKINNER J. J., Jr., SCHWARTZ M. J., SHURTLEFF D. Intermittent claudication. Incidence in the Framingham Study. Circulation, 1970, 41 (5) : 875-883.
23. ROTHWELL P. M., ELIASZIW M., GUTNIKOV S. A., WARLOW C. P., BARNETT H. J. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet, 2004, 363 (9413): 915-924.
24. TUNIS S. R., BASS E. B., STEINBERG E. P. The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease. N Engl J Med, 1991, 325 (8) : 556-562.
25. DORMANCY J., BELCHER G., BROOS P., EIKELBOOM B., LASZLO G., KONRAD P. et al. Prospective study of 713 below-knee amputations for ischaemia and the effect of a prostacyclin analogue on healing. Hawaii Study Group. Br J Surg, 1994, 81 (1) : 33-37.
26. BHATT D., STEG P., OHMAN E., HIRSCH A., IKEDA Y, MAS J. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA, 2006, 295 : 180-189.
27. ARONOW W. S., AHN C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol, 1994, 74 (1) : 64-65.
28. DORMANDY J. A., MURRAY G. D. The fate of the claudicant a prospective study of 1969 claudicants. Ear J Vase Surg, 1991, 5 (2): 131-133.
29. MEHLER P. S., COLL J. R., ESTACIO R., ESLER A., SCHRIER R. W., HIATT WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation, 2003, 107 (5) : 753-756.
30. CRIQUI M., LANGER R., FRONEK A., FEIGELSON H., KLAUBER M., MCCANN T. et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med, 1992, 326 : 381-386.
31. FOWKES F., LEE A., MURRAY G. on behalf of the ABI collaboration. Anklebrachial index as an independent indicator of mortality in fifteen international population cohort studies. Circulation, 2005, 112 : 3704.
32. CAPRIE. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348 (9038) : 1329-1339.
33. HPSCG. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals : a randomised placebo-controlled trial. Lancet, 2002, 360 (9326) : 7-22.
34. RESNICK H. E., LINDSAY R. S., MCD ERMOTT M. M., DEVEREUX R. B., JONES K. L., FABSITZ R. R. et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality : the Strong Heart Study. Circulation, 2004, 109 (6) : 733-739.
35. CRITCHLEY J. A., CAPEWELL S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease : a systematic review. JAMA, 2003, 290 (1) : 86-97.
36. ANTHONISEN N. R., SKEANS M. A., WISE R. A., MANFREDA J., KANNER R. E., CONNETT J. E. The effects of a smoking cessation intervention on 14.5-year mortality : a randomized clinical trial. Ann Intern Med, 2005, 142 (4) : 233-239.
37. TONSTAD S., FARSANG C., KLAENE G., LEWIS K., MANOLIS A., PERRUCHOUD A. P. et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease : a multicentre, randomised study. Eur Heart J, 2003, 24 (10) : 946-955.
38. JORENBY D. E., LEISCHOW S. J., NIDES M. A., RENNARD S. I., JOHNSTON J. A., HUGHES A. R. et al, A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engt J Med, 1999, 340 (9) : 685-691.
39. WILLIGENDAEL E. M., TEUINK J. A., BARTELINK M. L., PETERS R. J., BULLER H. R., PRINS M. H. Smoking and the patency of lower extremity bypass grafts : a meta-analysis. J Vase Surg, 2005, 42 (1): 67-74.
40. BAIGENT C., KEECH A., KEARNEY P. M., BLACKWELL L., BUCK G., POLLICINO C. et al. Efficacy and safety of cholesterol-lowering treatment : prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366 (9493) : 1267-1278.
41. DE BACKER G., AMBROSIONI E., BORCH-JOHNSEN K., BROTONS C., CIFKOVA R., DALLONGEVILLE J. et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis, 2004, 173 (2): 381-391.
42. GRUNDY S. M., CLEEMAN J. I., MERZ C. N., BREWER H. B., Jr., CLARK L. T., HUNNINGHAKE D. B. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 2004, 110 (2) : 227-239.
43. SMITH S. C., Jr., BLAIR S. N., BONOW R. O., BRASS L. M., CERQUEIRA M. D., DRACUP K. et al. AHA/ACC Scientific Statement : AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease :, 2001 update : A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation, 2001, 104 (13) : 1577-1579.
44. RUBINS H. B., ROBINS S. J., COLLINS D., FYE C. L., ANDERSON J. W., ELAM M. B. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs HighDensity Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med, 1999, 341 (6) : 410-418.
45. BLANKENHORN D. H., AZEN S. P., CRAWFORD D. W., NESSIM S. A., SANMARCO M. E., SELZER R. H. et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation, 1991, 83 (2) : 438-447.
46. TAYLOR A. J., SULLENBERGER L. E., LEE H. J., LEE J. K., GRACE K. A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2 : a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation, 2004, 110 (23) : 3512-3517.
47. CHOBANIAN A. V., BAKRIS G. L., BLACK H. R., CUSHMAN W. C., GREEN L. A., IZZO J. L., Jr. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003, 42 (6) : 1206-1252.
48. ESH/ESC. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003, 21 (6) : 1011-1053.
49. YUSUF S., SLEIGHT P., POGUE J., BOSCH J., DAVIES R., DAGENAIS G. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342 (3) : 145-153.
50. RADACK K., DECK C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A metaanalysis of randomized controlled trials. Arch Intern Med, 1991, 151 (9) : 1769-1776.
51. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352 (9131):837-853.
52. DCCT. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol, 1995, 75 (14) : 894-903.
53. ADA. Standards of medical care in diabetes-2006. Diabetes Care, 2006, 29 Suppl 1 : S4-S42.
54. DORMANDY J. A., CHARBONNEL B., ECKLAND D. J., ERDMANN E., MASSI-BENEDETTI M., MOULES I. K. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events) : a randomised controlled trial. Lancet, 2005, 366 (9493): 1279-1289.
55. BONAA K., NJOLSTAD I., UELAND P., SCHIRMER H., TVERDAL A., STEIGEN T. et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. W Engl J Med, 2006, 354: 1578-1588.
56. LONN E., YUSUF S., ARNOLD M. J., SHERIDAN P., POGUE J., MICKS M. et al Homocysteine lowering with folic acid and B vitamins in vascular disease. W Engl J Med, 2006, 354 (15) : 1567-1577.
57. ATC. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal, 2002, 324 (7329) : 71-86.
58. ATC. Collaborative overview of randomised trials of antiplatelet therapy-I : Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Br Med J, 1994, 308 (6921) : 81-106.
59. CLAGETT P., SOBEL M., JACKSON M., LIP G., TANGELDER M., VERHAEGHE R. Antithrombotic therapy in peripheral arterial disease : The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest, 2004, 126 : S609-S626.
60. NERI SERNERI G. G., COCCHERI S., MARUBINI E., VIOLI F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease : the DAVID study. Eur Heart J, 2004, 25(20): 1845-1852.
61. JANZON L., BERGQVIST D., BOBERG J., BOBERG M., ERIKSSON I., LINDGARDE F. et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication, effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med, 1990, 227 (5) : 301-308.
62. YUSUF S., ZHAO F., MEHTA S. R., CHROLAVICIUS S., TOGNONI G., FOX K. K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001, 345 (7) : 494-502.
63. BHATT D., FOX K., HACKR W., BERGER P., BLACK H., BODEN W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006, 354 : 1706-1717.
64. MURRAY C. J., LAUER J. A., HUTUBESSY R. C., NIESSEN L., TOMIJIMA N., RODOERS A. et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol : a global and regional analysis on reduction of cardiovascular-disease risk. Lancet, 2003, 361 (9359) : 717-725.
65. FISCHER M. A., AVORN J. Economic implications of evidencebased prescribing for hypertension : can better care cost less ? JAMA, 2004, 291 (15) : 1850-1856.
66. GASPOZ J. M., COXSON P. G., GOLDMAN P. A., WILLIAMS L. W., KUNTZ K. M., HUNINK M. G. et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med, 2002, 346 (23) : 1800-1806.
67. LANCASTER T., SILAGY C., FOWLER G. Training health professionals in smoking cessation. Cochrane Database Syst Rev, 2000 (3) : CD000214.
68. SONG F., RAFTERY J., AVEYARD P., HYDE C., BARTON P., WOOLACOTT N. Costeffectiveness of pharmacological interventions for smoking cessation : a literature review and a decision analytic analysis. Medical Decision Making, 2002, 22 (Suppl) : S26-S37.
69. HILLSDON M., FOSTER C., THOROGOOD M. Interventions for promoting physical activity. Cockrane Database Syst Rev, 2005 (1) : CD003180.
70. LOWENSTEYN I., COUPAL L., ZOWALL H., GROVER S. A. The costeffectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardiopulm Rehabil, 2000, 20 (3): 147-155.
71. JONES L., GRIFFIN S., PALMER S., MAIN C., ORTON V., SCULPHER M. et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events : a systematic review and economic evaluation. Health Technol Assess, 2004, 8 (38) iiiiv, 1-196.
72. MIHAYLOVA B., BRIGGS A., ARMITAGE J., PARISH S., GRAY A., COLLINS R. Costeffectiveness of simvastatin in people at different levels of vascular disease risk : economic analysis of a randomised trial in 20,536 individuals. Lancet, 2005, 365 (9473) : 1779-1785.
73. LAMY A., YUSUF S., POGUE J., GAFNI A. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation, 2003, 107 (7) : 960-965.
74. ANTMAN E. M., ANBE D. T., ARMSTRONG P. W., BATES E. R., GREEN L. A., HAND M. et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the, 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation, 2004, 110 (9) : e82-e292.
75. GIBBONS R. J., ABRAMS J., CHATTERJEE K., DALEY J., DEEDWANIA P. C., DOUGLAS J. S. et al. ACC/AHA, 2002 guideline update for the management of patients with chronic stable angina-summary article : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol, 2003, 41 (1): 159-168.
76. EAGLE K. A., BERQER P. B., CALKINS H., CHAITMAN B. R., EWY G. A., FLEISCHMANN K. E. et al. ACC/AHA. guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the, 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol, 2002, 39 (3) : 542-553.
77. MCFALLS E. O., WARD H. B., MORITZ T. E., GOLDMAN S., KRUPSKI W. C., LITTOOY F. et al. Coronary-artery revascularization before elective major vascular surgery. NEngl J Med, 2004, 351 (27) : 2795-2804.
78. POLDERMANS D., BOERSMA E., BAX J. J., THOMSON I. R., PAELINCK B., VAN DE YEN L. L. et al. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J, 2001, 22 (15) : 1353-1358.
79. POLDERMANS D., BOERSMA E., BAX J. J., THOMSON I. R., VAN DE VEN L. L., B LANKENSTEUN J. D. et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiography Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med, 1999, 341 (24) : 1789-94.
80. KERTAI M. D., BOERSMA E., BAX J. J., THOMSON I. R., CRAMER M. J., VAN DE VEN L. L. et al. Optimizing long-term cardiac management after major vascular surgery : Role of betablocker therapy, clinical characteristics, and dobutamine stress echocardiography to optimize long-term cardiac management after major vascular surgery. Arch Intern Med, 2003, 163 (18) : 2230-2235.
81. ADAMS R. J., CHIMOWITZ M. I., ALPERT J. S., AWAD I.A., CERQUERIA M. D., FAYAD P. et al. Coronary risk evaluation in patients with transient ischemie attack and ischemie stroke : a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American eart Association/American Stroke Association. Circulation, 2003, 108 (10): 1278-1290.
82. CHATURVEDI S., BRUNO A., FEASBY T., HOLLOWAY R., BENAVENTE O., COHEN S. N. et al. Carotid endarterectomy - an evidence-based review : report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2005, 65 (6) : 794-801.
83. RUNDBACK J. H., SACKS D., KENT K. C, COOPER C., JONES D., MURPHY T. et al. Guidelines for the reporting of renal artery revascularization in clinical trials. J Vase Interv Radiol, 2003, 14 (9 Pt 2) : S477-S4792.
84. PLOUIN P. F., CLEMENT D. L., BOCCALON H., DORMANDY J., DURAND-ZALESKI I., FOWKES G. et al. A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia. Int Angiol, 2003, 22 (4) : 333-339.
85. MCDBRMOTT M. M., GREENLAND P., LIU K., GURALNIK J. M., CRIQUI M. H., DOLAN N, C. et al. Leg symptoms in peripheral arterial disease : associated clinical characteristics and functional impairment. JAMA, 2001, 286 (13) : 1599-1606.
86. CRIQUI M. H., FRONEK A., KLAUBER M. R., BARRETT-CONNOR E., GABRIEL S. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease : results from noninvasive testing in a defined population. Circulation, 1985, 71 (3) : 516-522.
87. GIBBONS R. J., BALADY G. J., BRICKER J. T., CHAITMAN B.R., FLETCHER G. F., FROELICHER V. F. et al. ACC/AHA, 2002 guideline update for exercise testing : summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the, 1997 Exercise Testing Guidelines). J Am Coll Cardiol, 2002, 40 (8): 1531-1540.
88. LABS K. H., DORMANDY J. A., JAEGER K. A., STUERZEBECHER C., HIATT W. R. Transatlantic conference on clinical trial guidelines in PAOD (Peripheral arterial occlusive disease) clinical trial methodology. Eur J Vasc Endovasc Surg, 1999, 18 (3) : 253-265.
89. GARDNER A., POEHLMAN E. Exercise rehabilitation programs for the treatment of claudication pain : a meta-analysis. JAMA, 1995, 274 : 975-980.
90. STEWART K., HIATT W., REGENSTEINER J., HIRSCH A. Exercise training for claudication. N Engl J Med, 2002, 347 (24) : 1941-1951.
91. HIATT W., WOLFEL E., MEIER R., REOENSTEINER J. Superiority of treadmill walking exercise vs. strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation, 1994, 90 : 1866-1874.
92. REGENSTEINER J., WARE J. J., MCCARTHY W., ZHANO P., FORBES W., HECKMAN J. et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease : meta-analysis of six randomized controlled trials. J Am Geriatr Soc, 2002, 50 (12) : 1939-1946.
93. DAWSON D., CUTLER B., HIATT W., HOBSON R., MARTIN J., BORTEY E. et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med, 2000, 109 (7) : 523-530.
94. PRATT C. Analysis of the cilostazol safety database. Am J Cardiol, 2001, 87 (12A) : 28D-33D.
95. LEHERT P., COMTE S., GAMAND S., BROWN T. M. Naftidrofuryl in intermittent claudication : a retrospective analysis. J Cardiovasc Pharmacol, 1994, 23 Suppl 3 : S48-S52.
96. BOCCALON H., LEHERT P., MOSNIER M. [Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication]. Ann Cardiol Angeiol (Paris), 2001, 50 (3) : 175-182.
97. KIEFFER E., BAHNINI A., MOUREN X., GAMAND S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol, 2001, 20 (1) : 58-65.
98. SPENGEL F., CLEMENT D., BOCCALON H., LIARD F., BROWN T., LEHERT P. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. Int Angiol, 2002, 21 (1) : 20-27.
99. BREVETTI G., DIEHM C., LAMBERT D. European multicenter study on Propionyl-lcarnitine in intermittent claudication. J Am Coll Cardiol, 1999, 34: 1618-1624.
100. HIATT W., GENSTEINER J., CREAGER M., HIRSCH A., COOKE J., OLIN J. et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med, 2001, 110 (8) : 616-622.
101. MOHLER III E., HIATT W., CREAGER M. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease, Circulation, 2003, 108 (12) : 1481-1486.
102. MONDILLO S., BALLO P., BARBATI R., GUERRINI F., AMMATURO T., AGRICOLA E. et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med, 2003, 114 (5) : 359-364.
103. GIROLAMI B., BERNARDI E., PRINS M., TEN CATE J., HETTIARACHCHI R., PRANDONI P. et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl : a meta-analysis. Arch Intern Med, 1999, 159 (4) : 337-345.
104. HOOD S. C., MOHER D., BARBER G. G. Management of intermittent claudication with pentoxifylline : meta-analysis of randomized controlled trials. Cmaj, 1996, 155 (8) : 1053-1059.
105. MOHER D., PHAM B., AUSEJO M., SAENZ A., HOOD S., BARBER G. Pharmacological management of intermittent claudication : a meta- analysis of randomised trials. Drugs, 2000, 59 (5) : 1057-1070.
106. COSMI B., CONTI E., COCCHERI S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev, 2001, CD001999.
107. COFFMAN J. Vasodilator drugs in peripheral vascular disease. N Engl J Med, 1979, 300 : 713-717.
108. MAXWELL A. J., ANDERSON B. E., COOKE J. P. Nutritional therapy for peripheral arterial disease : a double-blind, placebo-controlled, randomized trial of HeartBar. Vase Med, 2000,5 ( 1 ) : 11 -19.
109. HIATT W. R., KLEPACK E., NEHLER M., REOENSTEINER J. G., BLUE J., IMUS J. et al. The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease. Vase Med, 2004, 9 (4): 271-277.
110. THULESIUS O., LUNDVALL J., KROESE A., STRANDEN E., HALLBOOK T., BRUNES L. et al. Ketanseruvin intermittent claudication : effect on walking distance, blood pressure, and cardiovascular complications. J Cardiovasc Pharmacol, 1987, 9 (6) : 728-733.
111. VERSTRAETE M. The PACK trial : morbidity and mortality effects of ketanserin. Prevention of atherosclerotic complications. Vase Med, 1996, 1 (2) : 135-140.
112. HIATT W. R., HIRSCH A. T., COOKE J. P., OLIN J. W., BRATER D. C., CREAGER M. A. Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Vase Med, 2004, 9(1): 18-25.
113. NORGREN L., JAWIEN A., MATYAS L., RIBC-ER H., ARITA K. AND THE EUROPEAN MCI-9042 STUDY GROUP. Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A phase II European Study. Vase Med, 2006, 11: 75-83.
114. BELCH J., BELL P., CREISSEN DEA., DORMANDY J. A., KESTER R. C., MCCOLLUM R. D. et al. Randomised, placebo-controlled, doubleblind study evaluating the efficacy and safety of AS-013, a prostaglandin El prodrug, in patients with intermittent claudication. Circulation, 1997, 95 : 2298-2302.
115. LIEVRE M., MORAND S., BESSE B., FIESSINGER J., BOISSEL J. Oral beraprost sodium, a prostaglandin I (2) analogue, for intermittent claudication : a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation, 2000, 102 (4) : 426-431.
116. MOHLER III E., HIATT W., OLIN J., WADE M., JEFFS R., HIRSCH A. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin 12 analogue : a double-blinded, randomized, controlled trial. J Am Coll Cardiol, 2003, 41 (10) : 1679-1686.
117. DE BACKER T., VANDER STICHELE R., BOGAERT M. Buflomedil for intermittent claudication. Cochrane Database Syst Rev, 2001, CD000988.
118. DE BACKER T., VANDER STICHELE R., WARIE H., BOGAERT M. Oral vasoactivc medication in intermittent claudication : utile or futile ? Eur J Clin Pharmacol, 2000, 56 (3) : 199-206.
119. LAURORA G., AMBROSOLI L., CESARONE M. R., DE SANCTIS M. T., INCANDELA L., MARELI C. et al. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study. Panminerva Med, 1994, 36 (2) : 83-86.
120. STRANO A., FAREED J., SABBA C., ALBANO O., ALLEGRA C., CARLIZZA A. et al. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide : preliminary results in patients with peripheral arterial disease. Semin Thromb Hemost, 1991, 17 (Suppl 2) : 228-234.
121. VIOLI F., MARUBINI E., COCCHERI S., NENCI G. G. Improvement of walking distance by defibrotide in patients with intermittent claudication - results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study. Thromb Haemost, 2000, 83 (5) : 672-677.
122. LEDERMAN R., MENDELSOHN F., ANDERSON R., SAUCEDO J., TENAGLIA A., JB H. et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study) : a randomised trial. Lancet, 2002. 359 (9323) : 2053-2058.
123. RAJAOOPALAN S., MOHLER E. I., LEDERMAN R., MENDELSOHN F., SAUCEDO J., GOLDMAN C. et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease : a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation, 2003, 108 (16): 1933-1938.
124. ARMSTRONG D. G., LAVERY L. A. Diabetic foot ulcers : prevention, diagnosis and classification. Am Fam Physician, 1998, 57 (6): 1325-1332, 1337-1338.
125. REIBER G. E., VILEIKYTE L., BOYKO E. J., DEL AGUILA M., SMITH D. G., LAVERY L. A. et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care, 1999, 22 (1) : 157-162.
126. ARMSTRONG D. G., LAVERY L. A., KIMBRIEI. H. R., NIXON B. P., BOULTON A. J. Activity patterns of patients with diabetic foot ulceration : patients with active ulceration may not adhere to a standard pressure off-loading regimen. Diabetes Care, 2003, 26 (9) : 2595-2597.
127. MOULIK P. K., MTONGA R., GILL G. V. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003, 26 (2) : 491-494.
128. STRANDNESS D. J., SUMNER D. Hemodynamics for surgeons. In : New York, Grune & Stratton. 1975. p. 278-281.
129. FRANZK'K U.K., TALKE P., BERNSTEIN E. F., GOLBRANSON F. L., FRONEK A. Transcutaneous PO2 measurements in health and peripheral arterial occlusive disease. Surgery, 1982. 91 (2) : 156-163.
130. SMITH I., FRANKS P. J., GREENHALGH R. M., POULTER N. R., POWELL J. T. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg. 1996, 11 (4) : 402-408.
131. ADA. Consensus Development Conference on Diabetic Foot Wound Care (American Diabetes Association). Diabetes Care, 1999,22: 1354-1360.
132. NAUURS-FRANSSEN M. H., SLEEGERS R., HUIJBERTS M. S., WUNEN W., SANDERS A. P., WALENKAMP G. et al. Total contact casting of the diabetic foot in daily practice : a prospective follow-up study. Diabetes Care, 2005, 28 (2) : 243-247.
133. LIPSKY B. International consensus group on diagnosing and treating the infected diabetic foot. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev, 2004, 20 (Suppl 1) : S68-S77.
134. FRYKBERG R. An evidence based approach to diabetic foot infections. Am J Surg, 2003,186 : S44-S54.
135. NEHLER M. R., HIATT W. R., TAYLOR Jr. L. M. Is revascularization and limb salvage always the best treatment for critical limb ischemia ? J VasC Surg, 2003, 37 (3) : 704-708.
136. CUTSON T. M., BONGIORNI D. R. Rehabilitation of the older lower limb amputee : a brief review. J Am Geriatr Soc, 1996, 44 (11) : 1388-1393.
137. LIM R. C., Jr., BLAISDELL F. W., HALL A.D., MOORE W. S., THOMAS A. N. Below-knee amputation for ischEmic gangrene. Surg Gynecol Obstet, 1967, 125 (3) : 493-501.
138. POREDOS P., RAKOVEC S., GUZIC-SALOBIR B. Determination of amputation level in ischaemic limbs using tcPO2 measurement. Vasa, 2005, 34 (2) : 108-112.
139. RUCKLEY C. V., STONEBRIDOE P. A., PRESCOTT R. J. Skewflap versus long posterior flap in below-knee amputations : multicenter trial. J Vasc Surg, 1991, 13 (3) : 423-427.
140. SIRIWARDENA G. J., BERTRAND P. V. Factors influencing rehabilitation of arteriosclerotic lower limb amputees. J Rehabil Res Dev, 1991, 28(3):35-44.
141. HAOBERG E., BERLIN O. K., RENSTROM P. Function after throughknee compared with below-knee and above-knee amputation. Prosthet Orthot Int, 1992, 16 (3) : 168-173.
142. HOUGHTON A. D., TAYLOR P. R., THURLOW S., ROOTES E., MCCOLL I. Success rates for rehabilitation of vascular amputees : implications for preoperative assessment and amputation level. Br J Surg, 1992, 79 (8) : 753-755.
143. STIRNEMANN P., WALPOTH B., WURSTEN H. U., GRABER P., PARLI R., ALTHAUS U. Influence of failed arterial reconstruction on the outcome of major limb amputation. Surgery, 1992, 111 (4) : 363-368.
144. MCWHINNIE D. L., GORDON A. C., COLLIN J., GRAY D. W., MORRISON J. D. Rehabilitation outcome 5 years after 100 lowerlimb amputations. Br J Surg, 1994, 81 (11) : 1596-1599.
145. NEHLER M. R., COLL J. R., HIATT W. R., REGENSTEINER J. G., SCHNICKEL G. T., KLENKE W. A. et al. Functional outcome in a contemporary series of major lower extremity amputations. J Vasc Surg, 2003, 38(1): 7-14.
146. BALZER K., BECHARA G., BISLER H., CLEVERT H., DIEHM C., HEISIC G. et al. Placebokontrollierte, doppel-blinde Multicenter studie zur Wirksamkeit von Iloprost bei der Behandlung ischämischer Ruheschmerzen von Patienten mit peripheren arterillen Durchblutungsstörungen. Vasa, 1987, 20 (Suppl) : 379-381.
147. BROCK F. E., ABRI O., BAITSCH G., BECHARA G., BECK K., COROVIC D. et al. Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebocontrolled multicenter study with' a stable prostacyclin derivative. Schweiz Med Wochenschr, 1990, 120 (40) : 1477-1482.
148. DIEHM C., ABRI O., BAITSCH G., BECHARA G., BECK K., BREDDIN H. K. et al. Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebocontrolled multicenter study. Dtsch Med Wochenschr, 1989, 114 (20) : 783-788.
149. DIEHM C., HIBSCH-MILLER C., STAMMLER F. Intravenose prostaglandin El-Therapie bei Patienten mit peripherer arterieller Verschlusskrankheit (AVK) im Stadium III : Eine doppelblinde, placebo-kontrollierte Studie. In : Heinrich H, Bohme H, Rogatti W, editors. Prostaglandin E1-Wirkungen und therapeutische Wirksamheit. Heidelberg : Springer-Verlag, 1988. p. 133-143.
150. CIPROSTENE STUDY GROUP. The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. J Clin Pharmacol, 1991, 31: 81-87.
151. UK SEVERE LIMB ISCHEMIA STUDY GROUP. Treatment of limb threatening ischemia with intravenous Iloprost : A randomised double-blind placebo controlled study. Eur J Vasc Surg, 1991, 5 : 511-516.
152. GUILMOT J., DIOT E. FOR THE FRENCH ILOPROST STUDY GROUP. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analoque of prostacyclin : results of a French Multicentre trial. Drug Invest, 1991, 3:351-359.
153. NORGREN L., ALWMARK A., ANGQVIST K. A., HEDBERO B., BERGQVIST D., TAKOLANDER R. et al. A stable prostacyclin analogue (iloprost) in the treatment of ischaemic ulcers of the lower limb. A Scandinavian-Polish placebo controlled, randomised multicenter study. Eur J Vasc Surg, 1990, 4 (5) : 463467.
154. SAKAGUCHI S. Prostaglandin El intra-arterial infusion therapy in patients with ischemic ulcer of the extremities. Int Angiol, 1984, 3 : 39-42.
155. BRASS E. P., ANTHONY R., DORMANDY J., HIATT W. R., JIAO J., NAKANISHI A. et al. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter sixmonth outcomes in patients with critical leg ischemia. J Vasc Surg, 2006, 43 (4) : 752-759.
156. DORFFLER-MELLY I., KOOPMAN M. M., ADAM D. J., BULLER H. R., PRINS MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev, 2003 (3) : CD000535.
157. SMITH F. B., BRADBURY A. W., FOWKES F. O. Intravenous naftidrofuryl for critical limb ischaemia. Cochrane Database Syst Rev. 2000 (2) : CD002070.
158. EUROPEAN STUDY GROUP. Intravenous pentoxifyllin. Eur J Vasc Endovasc Surg, 1995, 9 : 426-436.
159. NORWEGIAN PENTOXIFYLLIN MULTICENTER TRIAL GROUP. Efficacy and clinical tolerance of parenteral pentoxifyllin. Int Angiol, 1996, 15:75-80,
160. KRANKE PEA. Cochrane Database Systematic review. Cochrane I Database Syst Rev, 2004, CD004123.
161. UBBINK D. T., VERMEULEN H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev, 2003 (3) : CD004001.
162. CARDENAS D. D., HASELKORN J. K., MCELLIOGTT J. M., GNATZ S. M. A bibliography of cost-effectiveness practices in physical medicine and rehabilitation : AAPM&R white paper. Arch Phys Med Rehabil, 2001, 82 (5) : 711-719.
163. OOSTENBRINK J. B., TANGELDER M. J., BUSSCHBACH J. I., VAN HOUT B. A., BUSKENS E., ALGRA A. et al. Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. J Vasc Surg, 2001, 34 (2) : 254-262.
164. SARAC T. P., HILLEMAN D., ARKO F. R., ZARINS C. K., OURIEL K. Clinical and economic evaluation of the trellis thrombectomy device for arterial occlusions : preliminary analysis, J Vasc Surg, 2004, 39 (3) : 556-559.
165. WHATLING P. J., GIBSON M., TORRIE E. P., MAOEE T. R., GALLAND R. B. Iliac occlusions : stenting or crossover grafting ? An examination of patency and cost. Eur J VasC Endavasc Surg, 2000, 20 (1) : 36-40.
166. WIXON C. L., MILLS J. L., WESTERBAND A., HUGHES J. D., IHNAT D. M. An economic appraisal of lower extremity bypass graft maintenance. J Vasc Surg, 2000, 32 (1) : 1-12.
167. BAUMGARTNER I., PIECZEK A., MANOR O., BLAIR R., KEARNEY M., WALSH K. et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation, 1998, 97 (12): 1114-1123.
168. YLA-HERTTUALA S., ALITALO K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med, 2003, 9 (6) : 694-701.
169. TATEISHI-YUYAMA E., MATSUBARA H., MUROHARA T., IKEDA U., SHINTANI S., MASAKI H. et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells : a pilot study and a randomised controlled trial. Lancet, 2002, 360 (9331) : 427-435.
170. NORGREN L. Pharmacotherapy for critical limb ischaemia. Diabetes Metab Res Rev, 2000, 16 (Suppl 1) : S37-S41.
171. COLLINSON D. J., DONNELLY R., Therapeutic angiogenesis in peripheral arterial disease : can biotechnology produce an effective collateral Circulation ? Eur J Vasc Endovasc Surg, 2004, 28 (1) : 9-23.
172. BERRIDGE D., KESSEL D., ROBERTSON I. Surgery versus thrombolysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev, 2002, CD002784 (1).
173. CAMPBELL W., RIDLER B., SZYMANSKA T. Current management of acute leg ischaemia : results of an audit by the Vascular Surgical Society of Great Britain and Ireland. Br J Surg, 1998, 85 : 1498-1503.
174. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg, 1994, 220 : 251-266.
175. RUTHERFORD R. B., BAKER J. D., ERNST C., JOHNSTON K. W., PORTER J. M., AHN S. et al. Recommended standards for reports dealing with lower extremity ischemia : revised version. J Vasc ; Surg, 1997, 26 (3): 517-538.
176. KUUKASJARVI P., SALENIUS J. Perioperative outcome of acute lower limb ischaemia on the basis of the national vascular registry. The Finnvasc Study Group. Eur J Vasc Surg, 1994, 8 : 578-583.
177. ELIASON J. L., WAINESS R. M., PROCTOR M. C., DIMICK J. B., COWAN J. A., Jr., UPCHURCH G. R., Jr. et al. A national and single institutional experience in the contemporary treatment of acute lower extremity ischemia. Ann Surg, 2003, 238 (3) : 382-389, discussion 389-390.
178. OURIEL K., SHORTELL C., DEWEESE J., GREEN R., FRANCIS C., AZODO M. et al, A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg, 1994, 19: 1021-1030.
179. OURIEL K., VEITH F., SASAHARA A. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med, 1998, 338: 1105-1111.
180. KORN P., KHILNANI N. M., FELLERS J. C., LEE T. Y, WINCHESTER P. A., BUSH H. L. et al. Thrombolysis for native arterial occlusions of the lower extremities : clinical outcome and cost. J Vasc Surg, 2001, 33 (6) : 1148-1157.
181. SAKET R. R., RAZAVI M. K., PADIDAR A., KEE S. T., SZE D. Y., DAKE M. D. Novel intravascular ultrasound-guided method to create transintimal arterial communications : initial experience in peripheral occlusive disease and aortic dissection. J Endovasc Ther, 2004, 11 (3) : 274-280.
182. BECKER G. J., KATZEN B. T., DAKE MD. Noncoronary angioplasty. Radiology, 1989, 170 (3 Pt 2) : 921-940.
183. RUTHERFORD R., DURHAM J. Percutaneous ballon angioplasty for arteriosclerosis obliterans : long term results. In : YAO J., PEARCE W. (eds.). Techniques in Vascular Surgery. Philadelphia : Saunders, 1992, p. 329-345.
184. MURPHY T. P., ARIARATNAM N. S., CARNEY W. I., Jr., MARCACCIO E. J., SLAIBY J. M., SOARES G. M. et at. Aortoiliac insufficiency : long-term experience with stent placement for treatment. Radiology, 2004, 231 (1) : 243-249.
185. TIMARAN C. H., STEVENS S. L., FREEMAN M. B., GOLDMAN M. H. External iliac and common iliac artery angioplasty and stenting in men and women. J Vasc Surg, 2001, 34 (3) : 440-446.
186. TETTEROO E., VAN DER GRAAF Y., BOSCH J. L., VAN ENOELEN A. D., HUNINK M. G., EIKELBOOM B. C. et at. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliacartery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet, 1998, 351 (9110): 1153-1159.
187. KLEIN W. M., VAN DER GRAAF Y., SEEGERS J., MOLL F. L., MALI W. P. Long-term cardiovascular morbidity, mortality, and reintervention after endovascular treatment in patients with iliac artery disease : The Dutch Iliac Stent Trial Study. Radiology, 2004, 232(2): 491-498.
188. BOSCH I. L., HUNINK M. G. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology, 1997, 204 (1) : 87-96.
189. PONEC D., JAFF M. R., SWISCHUK J., FEIRING A., LAIRD J., MEHRA M. et al. The Nitinol SMART stent vs Wallstent for suboptimal iliac artery angioplasty : CRISP-US Trial results. J Vasc Interv RadioL. 2004, 15 (9): 911-918.
190. REED A., CONTE M., DONALDSON M., MANNICK J., WHITTEMORE A., BELKIN M. The impact of patient age and aortic size on the results of aortobifemoral bypass grafting. J Vasc Surg, 2003, 37 : 1219-1225.
191. DE VRIES S., HUNINK M. Results of aortic bifurcation grafts for aortoiliac occlusive disease : a meta-analysis. J Vasc Surg, 1997, 26 (4) : 558-569.
192. MURADIN G., BOSCH J., STIJNEN T., HUNINK M. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease : meta-analysis. Radiology, 2001, 221 (1) : 137-145.
193. LONDON N., SRINWASAN R., NAYLOR A., HARTSHORNE T., RATLIFF D., BELL P. et al. SubintimaL angioplasty of femoropopliteal artery occlusions : the long-term results. Eur J Vasc Surg, 1994, 8 (2) : 148-155.
194. DESGRANGES P., BOUFI M., LAPEYRE M., TARQUINI G., VAN LAERL O., LOSY F. et al. Subintimal angioplasty : feasible and durable. Eur J Vasc Endovasc Surg, 2004, 28 (2) : 138-141.
195. CEINA M., THURNHER S., ILLIASCH H., HORVATH W., WALDEN-RERGFR P., HORNIK K. et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions : a multicenter prospective randomized study. J Vasc InteRV- Radial, 200J, 12(1): 23-31.
196. GRIMM J., MULLER-HULSBECK S., JAHNKE T., HILBERT C., BROSSMANN J., HELLER M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv- Radial, 2001, 12 (8) : 935-942.
197. VROEOINDEWEIJ D., VOS L., TIELBEEK A., BURN J., VAN DER BOSCH H. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions : A comparative randomized study. Cardiovase Intervent Radial, 1997, 20 (6) : 420-425.
198. SCHILUNGER M., EXNER M., MLEKUSCH W., RUMPOLD H., AHMADI R., SABETI S. et al. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery : association with restenosis. Radiology, 2002, 225 (1) : 21-26.
199. SCHILLINGER M., SABETI S., LOEWE C., DICK P., AMIOHI J., MLEKUSCH W. et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N EngL J Med, 2006, 354 (18): 1879-88.
200. WOLF G., WILSON S., CROSS A., DEUPREE R., STASON W. Surgery or balloon angioplasty for peripheral vascular disease : a randomized clinical trial. Principal investigators and their Associates of Veterans Administration Cooperative Study Number, 199. J Vasc Interv Radial, 1993, 4 (5) : 639-648.
201. ADAM D. J., BEARD J. D., CLEVELAND T., BEI.L J., BRADBURY A. W., FORBES J. F. et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL) : multicentre, randomised controlled trial. Lancet. 2005, 366 (9501) : 1925-1934.
202. CONTE: M., BELKIN M., UPCHURCH G., MANNICK J., WHITTEMORE A., DONALDSON M. Impact of increasing comorbidity on infrainguinal reconstruction : a 20 year perspective. Ann Surg, 2001, 233:445-452.
203. LAM E., LANDRY G., EDWARDS J., YEAGER R., TAYLOR L., MONETA G. Risk factors for autogenous infrainguinal bypass occlusion in patients with prosthetic inflow grafts. J Vasc Surg. 2004, 39 : 336-342.
204. ALBERS M., BATTISTELLA V., ROMITI M., RODRIGUES A., PEREIRA C. Meta-analysis of polytctrafluocthylene bypass grafts to infrapopliteal arteries. J Vasc Surg, 2003. 37 : 1263-1269.
205. JACKSON M. R., BKLOTT T. P., DICKASON T., KAISER W. J., MODRAIL J. G., VALENTINE R. J. et al. The consequences of a failed femoropopliteal bypass grafting : comparison of saphenous vein and PTFE grafts, J Vasc Surg. 2000. 32 (3) : 498-504. 504-505.
206. GREEN R., ABBOTT W., MATSUMOTO T., WHEEIER J. R., MILLER N., VEITH F. J. tt at. Prosthetic above-knee femoropopliteal bypass grafting : five-year results of a randomized trial. J Vasc Surg. 2000,31:417-425.
207. ABURAHMA A. F., ROBINSON P. A., HOLT S. M. Prospective controlled study of polytetrafluoroethylene versus saphenous vein in claudicant patients with bilateral above knee femoropopliteal bypasses. Surgery, 1999,126 (4) : 594-601, discussion 601-602.
208. JOHNSON W. C., LEE K. K. A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization : a prospective randomized Department of Veterans Affairs cooperative study. J Vasc Surg, 2000, 32 (2) : 268-277.
209. KLINKERT P., VAN DUK P. J., BRESLAU P. J. Polytetrafluoroethylene femorotibial bypass grafting : 5-year patency and limb salvage. Ann Vasc Surg, 2003, 17 (5) : 486-491.
210. HAMSHO A., NOTT D., HARRIS P. L. Prospective randomised trial of distal arteriovenous fistula as an adjunct to femoroinfrapopliteal PTFE bypass. Eur J Vasc Endovasc Surg, 1999. 17(3): 197-201.
211. GRIFFITH C., NAGY J., BLACK D., STONEBRIDOE P. Randomized clinical trial of distal anastomotic interposition vein cuff in infrainguinal polytetrafluoethylene bypass grafting. Br J Surg. 2004, 91: 560.
212. DAVIES A. H., HAWDON A. J., SYDES M. R., THOMPSON S.O. Is duplex surveillance of value after leg vein bypass grafting '.' Principal results of the Vein Graft Surveillance Randomised Trial (VGST). Circulation, 2005, 112 (13) : 1985-1991.
213. BALDWIN Z., PEARCE B., CURI M., DESAI T., MCKINSEY J., BASSIOUNY H. et al. Limb salvage following infrainguinal bypass graft failure. J Vasc Surg, 2004, 39 : 951-957.
214. TANOELDER M., LAWSON J., ALORA A., EIKELBOOM B. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in prevention of graft occlusion and ischemie events after infrainguinal bypass surgery. J Vasc Surg, 1999, 30 : 701-709.
215. GIROLAMI B., BERNARDI E., PRINS M., TEN CATE J., PRANDONI P., SIMIONI P. et al. Antiplatelet therapy and other interventions after revascularization procedures in patients with peripheral arterial disease : a meta-analysis. Eur J Vasc Endovasc Surg, 2000, 19 : 370-380.
216. DORFFLER-MELLY J., BULLER H., KOOPMAN M., ADAM D., PRINS M. Antithrombotic agents for preventing thrombosis after peripheral bypass surgery. Cochrane database Syst Rev, 2003 (CD000536).
217. VISSER K., IDU M. M., BUTH J., ENGEL G. L., HUNINK M. G. Duplex scan surveillance during the first year after infrainguinal autologous vein bypass grafting surgery : costs and clinical outcomes compared with other surveillance programs. J Vasc Surg. 2001, 33(1): 123-130.
218. DUDA S., PUSICH B., RICHTER G., LANDWEHR P., OLIVA V. TIELBEEK A. et al. Sirolimus-eluting stems for the treatment of obstructive superficial femoral artery disease : six-month results. emulation, 2002, 106 (12) : 1505-1509.
219. SAXON R., COFFMAN J., GOODING J., NATUZZI E., PONEC D. Longterm results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery : single center experience from a prospective, randomized trial. J Vasc Interv Radial, 2003, 14 (3) : 303-311.
220. MINAR E., POKRAJAC B., MACA T., AHMADI R., FELINER C., MITTLBOCK M. et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty : results of u prospective randomized study. Circulation, 2000. 102 (22) : 2694-2699.
221. RUTHERFORD R. B., LOWENSTEIN D. H., KLEIN M. F. Combining segmental systolic pressures and plethysmography to diagnose arterial occlusive disease of the legs. Am J Surg. 1979. 138 (2) : 211-218.
222. KOELEMAY M. J., LEGEMATE D. A., REEKERS J. A., KOEDAM N. A., BALM R., JACOBS M. J. Interobserver variation in interpretation of arteriography and management of severe lower leg arterial disease. Eur J Vasc Endovasc Surg. 2001, 21 (5) : 417-422.
223. DE VRIES M., NUENHUIS R. J., HOOGEVEEN R. M., DE HAAN M. W., VAN ENGELSHOVEN J. M., LEINER T. Contrast-enhanced peripheral MR angiography using SENSE in multiple stations : feasibility study. J Magn Reson Imaging, 2005, 21 (1) : 37-45.
224. VOGT F. M., AJAJ W., HUNOLD P., HERBORN C. U., QUICK H. H., DEBATIN J. F. et al. Venous compression at high-spatial-resoluiion three-dimensional MR angiography of peripheral arteries. Radiology, 2004, 233 (3) : 913-920.
225. DORWEILER B., NEUFANG A., SCHMIEDT W., OELERT H. Pedal arterial bypass for limb salvage in patients with diabetes mellitus. Eur J Vasc Endovasc Surg, 2002, 24 (4) : 309-313.
226. JAKOBS T. F., WINTERSPERGER B. J., BECKER C. R. MDCT-imaging of peripheral arterial disease. Semin Ultrasound CT MR, 2004. 25 (2) : 145-155.
227. OTA H., TAKASE K., IGARASHI K., CHIBA Y., HAGA K., SAITO H. et al. MDCT compared with digital subtraction angiography for assessment of lower extremity arterial occlusive disease : importance of reviewing cross-sectional images. AJR Am J Roentgenol, 2004, 182 (1) : 201-209.